NASDAQ:TOI - Nasdaq - US68236X1000 - Common Stock - Currency: USD
ONCOLOGY INSTITUTE INC/THE
NASDAQ:TOI (2/5/2025, 8:00:01 PM)
After market: 0.84 -0.01 (-1.08%)0.8492
-0.03 (-3.5%)
The current stock price of TOI is 0.8492 USD. In the past month the price increased by 169.25%. In the past year, price decreased by -58.98%.
New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care
New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care...
TOI will be one of the few community-based practices on the West Coast to offer radiopharmaceuticals in the outpatient setting.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
HCA | HCA HEALTHCARE INC | 15.23 | 85.32B | ||
THC | TENET HEALTHCARE CORP | 13.01 | 13.79B | ||
BKDT | BROOKDALE SENIOR LIVING - BKD 7 11/15/25 | N/A | 13.68B | ||
UHS | UNIVERSAL HEALTH SERVICES-B | 13.01 | 12.75B | ||
EHC | ENCOMPASS HEALTH CORP | 24.28 | 10.30B | ||
ENSG | ENSIGN GROUP INC/THE | 28.14 | 8.53B | ||
ACHC | ACADIA HEALTHCARE CO INC | 12.82 | 4.18B | ||
SGRY | SURGERY PARTNERS INC | 27.44 | 3.28B | ||
CON | CONCENTRA GROUP HOLDINGS PAR | 8.73 | 2.97B | ||
SEM | SELECT MEDICAL HOLDINGS CORP | 9.48 | 2.62B | ||
PACS | PACS GROUP INC | 19.18 | 2.26B | ||
ARDT | ARDENT HEALTH PARTNERS INC | 39.68 | 2.15B |
The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California and currently employs 800 full-time employees. The company went IPO on 2020-03-13. The firm manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The firm's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The company also provides management services to 14 clinic locations owned by independent oncology practices. The firm and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
ONCOLOGY INSTITUTE INC/THE
18000 Studebaker Rd, Suite 800
Cerritos CALIFORNIA US
CEO: Steven Hochberg
Employees: 800
Company Website: https://theoncologyinstitute.com/
Investor Relations: https://investors.theoncologyinstitute.com/
Phone: 15627353226
The current stock price of TOI is 0.8492 USD.
The exchange symbol of ONCOLOGY INSTITUTE INC/THE is TOI and it is listed on the Nasdaq exchange.
TOI stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TOI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TOI.
TOI does not pay a dividend.
TOI does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
The outstanding short interest for TOI is 0.58% of its float.
ChartMill assigns a technical rating of 9 / 10 to TOI. When comparing the yearly performance of all stocks, TOI is one of the better performing stocks in the market, outperforming 96.2% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TOI. TOI has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months TOI reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by -6.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -32.07% | ||
ROE | -371.14% | ||
Debt/Equity | 5.91 |
ChartMill assigns a Buy % Consensus number of 84% to TOI. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 38.52% and a revenue growth 29.38% for TOI